• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    11/27/23 12:30:58 PM ET
    $ABEO
    $BDRX
    $CYTO
    $HARP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email

    Gainers

    • Redhill Biopharma (NASDAQ:RDHL) shares rose 207.0% to $0.97 during Monday's regular session. The company's market cap stands at $10.7 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 119.89% to $6.13. The company's market cap stands at $4.2 million.
    • Tharimmune (NASDAQ:THAR) shares moved upwards by 27.3% to $3.66. The market value of their outstanding shares is at $2.5 million.
    • Lexaria Bioscience (NASDAQ:LEXX) stock rose 24.42% to $1.63. The company's market cap stands at $15.8 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock increased by 21.06% to $3.96. The market value of their outstanding shares is at $58.5 million.
    • Abeona Therapeutics (NASDAQ:ABEO) stock rose 19.02% to $5.13. The market value of their outstanding shares is at $126.7 million.

    Losers

    • Harpoon Therapeutics (NASDAQ:HARP) shares decreased by 25.1% to $8.96 during Monday's regular session. The company's market cap stands at $151.6 million.
    • Telesis Bio (NASDAQ:TBIO) stock fell 21.24% to $0.32. The company's market cap stands at $9.5 million.
    • Altamira Therapeutics (NASDAQ:CYTO) shares decreased by 19.09% to $0.23. The company's market cap stands at $1.8 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock fell 17.21% to $0.86. The market value of their outstanding shares is at $3.1 million.
    • Kazia Therapeutics (NASDAQ:KZIA) shares fell 14.29% to $0.6. The market value of their outstanding shares is at $14.1 million.
    • UpHealth (NYSE:UPH) stock fell 14.1% to $0.52. The market value of their outstanding shares is at $8.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $BDRX
    $CYTO
    $HARP

    CompanyDatePrice TargetRatingAnalyst
    Abeona Therapeutics Inc.
    $ABEO
    6/2/2025$19.00Outperform
    Oppenheimer
    Abeona Therapeutics Inc.
    $ABEO
    3/5/2025$16.00Outperform
    Oppenheimer
    Kazia Therapeutics Limited
    $KZIA
    2/6/2025$3.00Buy
    Maxim Group
    Abeona Therapeutics Inc.
    $ABEO
    7/3/2024$15.00Buy
    H.C. Wainwright
    Abeona Therapeutics Inc.
    $ABEO
    5/30/2024$21.00Buy
    Stifel
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    Harpoon Therapeutics Inc.
    $HARP
    1/5/2024$23.00Outperform
    Oppenheimer
    Harpoon Therapeutics Inc.
    $HARP
    11/20/2023Outperform
    TD Cowen
    More analyst ratings

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Aminov Erez was granted 125,000 shares, exercised 613,595 shares at a strike of $0.96 and sold $1,294,685 worth of shares (613,595 units at $2.11), increasing direct ownership by 4% to 3,592,666 units (SEC Form 5)

    5 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

    2/17/26 8:30:02 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Radkowski Angela Dominy

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:20:49 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sommers Jill E.

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:18:29 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bunka Christopher bought $25,241 worth of shares (27,500 units at $0.92) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 5:12:54 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mckechnie William Edward bought $4,532 worth of shares (5,000 units at $0.91), increasing direct ownership by 38% to 18,191 units (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 12:37:08 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CSO Docherty John Martin bought $4,989 worth of shares (5,376 units at $0.93) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 11:34:10 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

    March 9, 2026 Biodexa Announces Support for Life's a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated

    3/9/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

    CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will b

    3/3/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Abeona Therapeutics with a new price target

    Oppenheimer resumed coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $19.00

    6/2/25 8:44:24 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Abeona Therapeutics with a new price target

    Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00

    3/5/25 7:50:58 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00

    2/6/25 7:53:38 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    SEC Filings

    View All

    Abeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    3/9/26 7:30:53 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)

    3/3/26 4:01:24 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Financials

    Live finance-specific insights

    View All

    Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

    CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will b

    3/3/26 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

    - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the third quarter of 2025 and shared recent operational progress. "We are scaling the ZEVASKYN launch to meet patient needs

    11/12/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

    CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 877-545-0523 (U.S. toll-free) or 973-528-0016 (international) and Entry Code: 922481 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona's website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available

    11/7/25 7:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $BDRX
    $CYTO
    $HARP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care